# QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

> **NCT04515797** · PHASE4 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 2 (actual)

## Conditions studied

- Kidney Failure
- Hepatitis C
- Kidney Disease, Chronic

## Interventions

- **DRUG:** Glecaprevir and Pibrentasvir

## Key facts

- **NCT ID:** NCT04515797
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Unable to meet enrollment goal prior to drug expiration
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515797, "QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04515797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*